世界主要5間製藥企業：現狀及今後動向 是由出版商i3 Consult在2008年08月所出版的。
這份英文市場調查報告書包含20+ pages 價格從美金1000起跳。
Abstract
Scope
- Financial investors reviewing their portfolio in pharma market shares
- Big pharma CFOs wanting to gauge their company performance against other
competitors
- Product Managers needing a gap analysis of portfolios and pipelines
- All Strategy Managers in the pharma market
Report Highlights
This report presents the cases of the top five global pharma companies: J&J,
Pfizer, GSK, Novartis and Sanofi-Aventis and identifies their key growth
areas. Pooling data from 6 major investment institutions, it delivers a 360o
analysis on these big five global pharma with further value add and refinement
coming from 8 leading key opinion leaders, to produce an easy to read 25 page
PowerPoint deck.
Johnson & Johnson has reached a critical point in its product portfolio which
should see the company convert from “cash cow” (high market share;
low market growth) to “star” (high market share; high market
growth) status by 2010. This is reflected in J&J having not less than 6 late
stage drugs that will either unveil phase III data or be filed with the FDA
within 2008 culminating in strong impact on its P&L account by 2010.
Likewise the other cash cow Pfizer, boasts of at least 17 disclosed products
under late phase development, with launches in the post-2010 period, thus are
likely to buoy double digit sales growth beyond Lipitor patent expiry.
GlaxoSmithKline on the other hand, has a product portfolio with a significant
cash flow position this in turn has spurred on a meaningful gearing by GSK
management. This puts the company firmly in a star performing position for
2008-2011. With asset consolidation of $23.5bn USD over three years post-2009,
the company is likely to attain double-digit earnings growth out to 2011 with
mid-digit growth in 2012 impacted by generic competition.
In the same star category is Novartis with top-line growth driven by a
combination of solid cash generating franchises (Diovan, Gleevec) revealing
steady growth and an extensive and rich research pipeline with potential to
generate as many as 4-6 new filings per year 2008-2011.
Sanofi-Aventis' strong 2008 second quarter performance qualifies the company
as a star company however this status is likely to come under threat; key
impacts are from the risk of generic Plavix during 2008-2011 and high
investment phase III projects lacking in validated data with pivotal results
for Acomplia for example awaiting on CRESCENDO study results not scheduled for
release until 2010, thus potentially sliding the company into “question
mark” (low market share; high market growth) status.
Analysis of “buys” on the basis of EPS growth rates against market
peers reveals, GlaxoSmithKline (14% against EU rate of 8%) and Johnson &
Johnson (14% against US peer rate of 9%) are preferred over the three other
companies researched.
PEG ratios between 1 and 2 are considered to be in the range of normal values
for pharma. Pooled analysis suggests that companies with PEG values between 0
to 1 may provide higher returns and so the decreasing order of returns is: GSK
(0.98), J&J (1.24), Pfizer (1.36), Novartis (1.56) and Sanofi-Aventis (2.42).
Such “ear-on-ground” knowledge of the big five pharma drug
portfolios has been carefully compiled in this study by independent assessment
of investment worth based on an unbiased analyst pool.
Reasons to Purchase
- Gain “ear-on-ground” knowledge on key drivers of big five
pharma drug portfolios
- Independent assessment of investment worth based on unbiased analyst pool
- Easy reading format for rapid distillation of information
Table of Contents
- The Who, What, Where, How and Why of this Report
- Key Take-Aways
- Table 1: Which Top Five Global Pharma are Chosen?
- Chart 1: Net Income per Employee against R&D Expenditures
- Johnson & Johnson Case Study
- Table 2: J&J' s New Medical Entity Filings 2007-2010
- Pfizer Case Study
- Table 3: Pfizer' s New Medical Entity Filings 2010 and Beyond
- GlaxoSmithKline Case Study
- Table 4: Sales & Success Estimates for GSK' s Early Phase-Clinically
Superior Pipeline
- Novartis Case Study
- Table 5: Novartis' Scheduled NME Filings from 2008 to Beyond 2011
- Sanofi-Aventis Case Study
- Table 6: Sanofi-Aventis' Short-Term NME Filings
- Table 7: PEG Ratio Valuation
- Chart 2: PEG Ratio Valuation
- Table 8: BCG Analysis
- Chart 3: BCG Matrix of Global Pharma
- Interpretation of BCG Matrix (Chart 3)
- Appendix - Financial Terminology
- Disclaimer
